Navigation Links
Washington Capitals to Visit Patients at Children's National Medical Center, Announce Launch of Initiative to Fight Pediatric Cancer
Date:10/11/2007

WASHINGTON, Oct. 11 /PRNewswire-USNewswire/ -- Monday will be a little cooler for the patients at Children's National Medical Center, when owner Ted Leonsis and the entire Washington Capitals team will make their annual visit. The team will also launch its new initiative to raise money for cancer research, Courage Caps.

Courage Caps are team-issued and branded hats that will be sold throughout the season at Capitals home games and online at NHL.com, with 100 percent of the sale price going toward cancer research.

WHO: Washington Capitals players, coaches, and chairman and

majority owner Ted Leonsis

WHAT: Press conference and availability, as well as visits

with patients

WHEN: Monday, October 15

Press conference and patient visit in Atrium,

2:00-2:45 p.m.

WHERE: Children's National Medical Center

Atrium (main lobby)

111 Michigan Avenue., NW

Washington, DC 20010

The Capitals players may visit patient floors, but media will be allowed only for the events in the Atrium from 2:00 to 2:45 p.m.


'/>"/>
SOURCE Children's National Medical Center
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. Washington DC Residents To Be Tested For HIV
2. Gorilla Dies during Heart Surgery at Washington Zoo
3. Free Condoms Distribution to Prevent HIV in Washington
4. Washington Post Examines Increase in Minorities Seeking Cosmetic Surgery
5. Breastfeeding Revisited thanks to WHO and UNICEF
6. Soccer club visit to turkey, cancelled
7. French Minister To Visit La Reunion Island To Monitor Chikungunya Epidemic
8. Mind your looks for Bush visit, as world is watching
9. Baby Boomers Visit Doctors As Frequently As They Visit the Gym
10. Medicos visit religious place to drum up support
11. Bulk-billing rate pressure lowers hospital visits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...ewswire/ -- Intravenous patient-controlled analges... medication, but a new study published in the Dece...n Quality and Patient Safety shows that errors re...to result in patient harm than errors that occur w...re than 9,500 PCA errors over a five-year period i...
(Date:12/1/2008)...wire/ -- Mentice proudly announces,the launch of ...ing - the,Mentice VIST 7.7 enhanced training modu...eatures such as vital signs, complications, medica... to the clinical realism and,enhance the educatio...es like vital signs and complications imply a dyna...
(Date:12/1/2008)... -- Sciton introduces ProLipo,PLUS(TM), an FDA-cl...r system,for ablating and melting unwanted fat, r...ning. ProLipo PLUS combines 1064 nm and 1319 nm w...g results. Frequently used as an adjunct,to trad...standalone procedure,for patients who are not can...
(Date:12/1/2008)...the cutting-edge of intraoperative imaging , ,...althcare ( www.siemens.com/healthcare ) wil...R) C-Arm systems, featuring outstanding image qual...in the OR, at the 94th Scientific Assembly and Ann...merica (RSNA) from November 30 to December 5 at Mc...
Breaking Medicine News(10 mins):Health News:Study: Patient Harm More Common with Patient-Controlled Pain Medication 2Health News:Study: Patient Harm More Common with Patient-Controlled Pain Medication 3Health News:Mentice VIST(TM) New and Enhanced Carotid and Coronary Training Modules Take Medical Simulation Training to the Next Level 2Health News:Sciton Introduces ProLipo PLUS(TM), the Most Robust Laser-Assisted Lipolysis System Available 2Health News:Siemens Next-Generation of C-Arms Demonstrate Precision Imaging and Ease of Use 2Health News:Siemens Next-Generation of C-Arms Demonstrate Precision Imaging and Ease of Use 3
...nd Middle East doctor community is struggling to c...or attempts in the country, even more grisly detai...have given a cryptic clue about the foiled UK bomb... a British cleric in Baghdad that "those who cure ...
...or the first time identified human antibodies that...ponsible for the outbreaks of severe acute respira... from the United States Army Medical Research Inst...ID), scientists at the National Institutes of Heal...
...tors heading to Beijing for the Olympics should no... many safety measures are being put in place for t...rm over Chinese food exports has been building for... toxic produce endangering lives in the United Sta...
... Egypt's greatest female Pharaoh died in pain prob... a new study by researchers has revealed. The da...s II, her half-brother, Hatshepsut reigned from 14... the 18th Dynasty, whose later members included Ak...
Other Medicine News:Health News:Those Who Cure can Kill Dire Prophesy of the doctors Plot 2Health News:Scientists Identify Antibodies That Block Human and Animal SARS Viruses 2Health News:Beijing Says Food Safe for Olympic Athletes, Tourists 2Health News:Beijing Says Food Safe for Olympic Athletes, Tourists 3Health News:Pharaoh Hatshepsut Died in Pain Due to Cancer 2
(Date:11/25/2008)...ov. 25 Pharmacyclics, In...pany has completed a Phase 1,clinical trial with ...all-molecule Factor VIIa inhibitor. The trial was ...valuate the safety and pharmacologic effect of,PC...lted in a linear dose,response in the Internation...
(Date:11/24/2008)... OSAKA, Japan, Nov. 24 Takeda Phar...bsidiary, Takeda Global Research & Development...ritis Advisory Committee of the U.S. Food and Drug...rove febuxostat for the treatment of hyperuricemi...n favor of approval, with one panel member abstain...
(Date:11/24/2008)...ic Cancer Awareness Month , , Oak Brook, Il...an Society for Gastrointestinal Endoscopy (ASGE) a...g up this November to raise awareness about pancre...and the resources that are available for them. , ...use of cancer deaths in the U.S. In 2008, an estim...
(Date:11/24/2008)...v. 24 Schering-Plough Co...denant, its novel and selective adenosine2a recept... II dose-finding trial in patients suffering from ...g motor fluctuations and abnormal involuntary move...nted today at the company,s 2008 R&D Update me...
Breaking Medicine Technology:Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 2Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 4Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 2Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 3ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 2ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 3ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 4ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 5ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 6Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 2Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 3Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 4Study Confirms Anti Infective ARIKACE 28TM 29 Effectively Penetrates Mucus and Biofilm and Kills Pseudomonas a Bacteria Plaguing Cystic Fibrosis Pat 4270 1Study Confirms Anti Infective ARIKACE 28TM 29 Effectively Penetrates Mucus and Biofilm and Kills Pseudomonas a Bacteria Plaguing Cystic Fibrosis Pat 4270 2Study Confirms Anti Infective ARIKACE 28TM 29 Effectively Penetrates Mucus and Biofilm and Kills Pseudomonas a Bacteria Plaguing Cystic Fibrosis Pat 4270 3Study Confirms Anti Infective ARIKACE 28TM 29 Effectively Penetrates Mucus and Biofilm and Kills Pseudomonas a Bacteria Plaguing Cystic Fibrosis Pat 4270 4CryoLife Closes on 2415 Million Credit Facility with GE Healthcare Financial Services 4268 1CryoLife Closes on 2415 Million Credit Facility with GE Healthcare Financial Services 4268 2CryoLife Closes on 2415 Million Credit Facility with GE Healthcare Financial Services 4268 3Kingfisher Announces FDA 510 28k 29 Clearance of Breakthrough KFH Energy for Chronic Pain Sufferers 1635 1Kingfisher Announces FDA 510 28k 29 Clearance of Breakthrough KFH Energy for Chronic Pain Sufferers 1635 2Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 1633 1Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 1633 2Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 1633 3Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 1633 4
... SAN DIEGO, June 19, 2007 /PRNewswire-FirstCall/ -...t data featuring its,approved diabetes drugs, BYET...tide acetate) injection, and its pipeline,candidat...ciation,s,(ADA) 67th Annual Scientific Sessions be...mpany will also host an investor,presentation duri...
...Company-Sponsored Investor Briefing and Webcast to...7 /PRNewswire-FirstCall/ -- Biodel,Inc. today anno...ding product candidate, VIAject(TM), at the 67th A...ic Sessions, to be held in,Chicago, June 22 throug... will take place on June 22,from 4:15 - 6:15pm CST...
Other Medicine Technology:Amylin Pharmaceuticals to Present New Data from Broad Diabetes and,Obesity Programs at ADA 2007 2Amylin Pharmaceuticals to Present New Data from Broad Diabetes and,Obesity Programs at ADA 2007 3Amylin Pharmaceuticals to Present New Data from Broad Diabetes and,Obesity Programs at ADA 2007 4Biodel Inc. to Present VIAject Clinical Progress at the 2007,American Diabetes Association Meeting 2Biodel Inc. to Present VIAject Clinical Progress at the 2007,American Diabetes Association Meeting 3
The Infinity Amylase CPNG3 single liquid stable reagent offers the laboratory all the convenience of single liquid stability to help maximize laboratory productivity, minimize operator error and prov
The Infinity Urea single liquid stable reagent offers the laboratory all the convenience of single liquid stability to help maximize laboratory productivity, minimize operator error and provide quick
...t once reconstituted offers the laboratory all the...ximize laboratory productivity, minimize operator ...e proprietary technology of the Infinity Glucose H...e and stability once reconstituted that will minim...
The Infinity Amylase powder reagent once reconstituted offers the laboratory all the convenience of single liquid stability to help maximize laboratory productivity, minimize operator error and provi
Medicine Products: